Stockscreener 앱 받기
62.32
0.99%
-0.62
시간 외 거래:
62.90
0.58
+0.93%
전일 마감가:
$62.94
열려 있는:
$63.18
하루 거래량:
5.23M
Relative Volume:
1.65
시가총액:
$5.67B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-22.26
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+10.77%
1개월 성능:
+15.07%
6개월 성능:
+48.59%
1년 성능:
+25.92%
1일 변동 폭
$62.27
$64.18
1주일 범위
$55.68
$64.18
52주 변동 폭
$30.04
$71.13
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
62.32 | 5.72B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | JP Morgan | Overweight |
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
Crispr Therapeutics AG Surges Amid Analyst Praise - TipRanks
Hedges Asset Management LLC Has $1.20 Million Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Sold by Goldman Sachs Group Inc. - MarketBeat
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 1,262,560 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
First Week of November 21st Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
Jobs Data: Does CRISPR Therapeutics AG have pricing powerWeekly Gains Report & Reliable Price Breakout Signals - khodrobank.com
JPMorgan Chase & Co. Initiates Coverage on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
Aug Action: Is CRISPR Therapeutics AG stock good for income investors2025 Trading Volume Trends & Real-Time Sentiment Analysis - khodrobank.com
Patterns Watch: What is the long term forecast for CRISPR Therapeutics AG stock2025 Institutional Moves & Real-Time Market Sentiment Alerts - khodrobank.com
Hedge Fund Bets: Why is CRISPR Therapeutics AG stock going downWeekly Loss Report & Reliable Volume Spike Alerts - khodrobank.com
Millennium Management LLC Buys 575,235 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years - Benzinga
CRISPR Therapeutics (CRSP) Gains on J.P. Morgan's Overweight Rat - GuruFocus
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects - MSN
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Benzinga
JP Morgan Initiates Coverage of CRISPR Therapeutics (CRSP) with Overweight Recommendation - Nasdaq
CRSP: JP Morgan Initiates Coverage with Overweight Rating | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Growth and Strategic Opportunities Justify Buy Rating - TipRanks
CRISPR Therapeutics stock initiated with Overweight rating by JPMorgan - Investing.com India
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track (CRSP) - Seeking Alpha
CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion - MSN
Gene Editing Market Exclusive Report with Detailed Study & - openPR.com
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6.8%Here's Why - MarketBeat
Momentum Shift: Will CRISPR Therapeutics AG stock hit new highs in YEARLayoff News & Community Supported Trade Ideas - خودرو بانک
Aug Final Week: Is CRISPR Therapeutics AG a speculative investmentJuly 2025 News Drivers & Stepwise Entry and Exit Trade Signals - خودرو بانک
Aug Closing: Is CRISPR Therapeutics AG still a buy after recent gainsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - خودرو بانک
Earnings Report: Is LIQT forming a breakout patternInsider Selling & Fast Gaining Stock Strategy Reports - خودرو بانک
Genome Editing Market Forecast Report 2025-2030, with Profiles of Merck, Horizon Discovery, GenScript, Sangamo Therapeutics, Danaher, Lonza, BEX, OriGene Technologies, CRISPR Therapeutics, and More - uk.finance.yahoo.com
12,424 Shares in CRISPR Therapeutics AG $CRSP Acquired by Bayforest Capital Ltd - MarketBeat
Earnings Report: Can CRISPR Therapeutics AG stock outperform in a bear market2025 Price Action Summary & Advanced Swing Trade Entry Alerts - khodrobank.com
Investment Recap: Will CRISPR Therapeutics AG benefit from government policyWeekly Loss Report & Weekly Chart Analysis and Trade Guides - خودرو بانک
Institution Moves: What is the long term forecast for CRISPR Therapeutics AG stockJuly 2025 Price Swings & Safe Swing Trade Setups - khodrobank.com
Tech Rally: Is CRISPR Therapeutics AG showing insider buyingGold Moves & Free Expert Verified Stock Movement Alerts - khodrobank.com
What CRISPR Therapeutics (CRSP)'s Pipeline Updates and Casgevy Adoption Mean for Shareholders - simplywall.st
Loss Report: Is CRISPR Therapeutics AG a speculative investmentIndex Update & Real-Time Market Sentiment Alerts - خودرو بانک
CRISPR Therapeutics (CRSP): Revisiting Valuation in Light of New Clinical Data and Expanding Commercial Momentum - Yahoo Finance
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
CRISPR Therapeutics AG $CRSP Position Raised by Raymond James Financial Inc. - MarketBeat
Trexquant Investment LP Acquires Shares of 38,831 CRISPR Therapeutics AG $CRSP - MarketBeat
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - sharewise.com
CRISPR Therapeutics AG (CRSP)’s Casgevy Expands Global Adoption in 2025 - MSN
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):